Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cut to "Buy" at Vetr Inc

Price targets show what analysts believes a stock will be worth at the end of a certain time period. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.

In the most updated research from a number of analysts on Wall Street, the company gets 17 Buys and 0 Sell among 22 analysts.

Currently, 0.20% shares of The Estee Lauder Companies Inc. Zacks Investment Research cut Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, August 4th. Vertex Pharmaceuticals Incorporated has been given an analysts' mean target of 178.09. The stock closing price is now trading downward to its 50 day moving average with change of -5.96%, tumbled to its 20 day moving average with figure of -2.50% and behind its 200 day moving average with value -17.78%. Six equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company's stock.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at 157.215 on Tuesday. The overall volume in the last trading session was 9.1 million shares. Over the last five days, shares have faced -2.73% losses and now is up 41.27% since hitting its 200-day moving average of $125.51. The company has market cap of $40.04 billion. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.85.

Vertex Pharmaceuticals Incorporated (VRTX) now has a Return on Assets (ROA) value of 8.8 Percent. The Return on Investment (ROI) ratio of Vertex Pharmaceuticals Incorporated (VRTX) is -0.3 percent. The company had revenue of $544.10 million for the quarter, compared to analysts' expectations of $489.95 million. The Regal Investment Advisors Llc holds 46,487 shares with $4.85M value, down from 50,297 last quarter. On average, analysts predict that Vertex Pharmaceuticals will post $1.60 EPS for the current fiscal year.

Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company's stock worth $325,000 after acquiring an additional 23 shares in the last quarter. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright legislation. The correct version of this story can be accessed at Finally, Morgan Stanley increased its stake in shares of Vertex Pharmaceuticals by 269.3% in the third quarter. The share price has moved forward from its 20 days moving average, trading at a distance of 1.95% and stays 5.92% away from its 50 days moving average. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The shares were sold at an average price of $90.00, for a total transaction of $108,720.00. The disclosure for this sale can be found here. Also, EVP Stuart A. Arbuckle sold 1,208 shares of the company's stock in a transaction that occurred on Wednesday, November 9th.

Several large investors have recently modified their holdings of the stock. Guardian Life Insurance Co. of America lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the first quarter. Baillie Gifford & Co. grew its holdings in shares of Vertex Pharmaceuticals by 6.9% during the second quarter. The earnings per share (EPS) term represents portion of a company's earnings with net of taxes as well as preferred stock dividends that is owed to each share of common stock. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 3.5% during the 1st quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company's stock valued at $651,454,000 after buying an additional 3,626,368 shares during the period. Finally, RNC Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 5.3% in the second quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $203,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Like this


13 September 2017
Kathie Lee Gifford's mother Joan Epstein dies at 87
Kotb posted on her personal account a photo of her and Gifford with their mothers, writing "We will miss you sweet Joannie". She also opened up about how much her mother meant to her and how much she supported her in achieving her dreams.

13 September 2017
Gianni Infantino opposed blocking Vitaly Mutko, says former Federation Internationale de Football Association official Miguel Maduro
But travel problems meant Maduro will answer questions from legislators on the culture, media and sport committee on Wednesday morning.

13 September 2017
Janet Jackson's Brother Claims Wissam Al Mana 'Verbally Abused' Her During Marriage
Still, in a statement delivered to People , Al Mana's team claimed Randy's statements were false and completely inflammatory. Al Mana's attorney has addressed Randy's abuse allegations saying that they are untrue. "I didn't want them to know".

13 September 2017
Which insiders are trading TETRA Technologies, Inc. (TTI)?
Their average price target spell out an upbeat performance - a 104% and would give TTI a market capitalization of almost $502.13M. Paloma Ptnrs Management Co owns 38,026 shares. (NYSE:SE) has "Outperform" rating given on Monday, June 27 by RBC Capital Markets.

13 September 2017
Court Place Advisors LLC Acquires 1507 Shares of Intel Corporation
Moreover, Americafirst Cap Mngmt Ltd Liability has 0% invested in Intel Corporation (NASDAQ:INTC) for 10,900 shares. Bsw Wealth Ptnrs reported 0.14% stake. 781,717 shares or 148.35% more from 314,763 shares in 2016Q3 were reported.

13 September 2017
The TLP Group LLC Has $639000 Stake in Encana Corporation (ECA)
Wall Street analysts are predicting that Encana Corp (NYSE:ECA) will report earnings per share of $0.07 in their quarterly report. UBS AG raised Encana Corporation from an "outperform" rating to a "strong-buy" rating in a report on Wednesday, July 5th.

13 September 2017
Junior Cert results day for Kilkenny students
Five pupils at one Limerick school are celebrating after they each achieved nine As in the in their Junior Cert exams. Some 3,240 students in the county will receive the results of last June's exams from their schools today.

13 September 2017
Vantiv, Inc. Class A (NYSE:VNTV) Experiences Heavier than Usual Trading Volume
August 11 investment analysts at Citigroup left the stock rating at "Buy" and raised the price expectation from $46.50 to $74.00. The business services provider reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.82 by $0.01.

13 September 2017
Summit Midstream Partners, LP (NYSE:SMLP) Updated Broker Ratings
Analysts forecast that Magellan Midstream Partners L.P. will post $3.91 earnings per share for the current fiscal year. Sequoia Financial Advisors LLC raised its position in Magellan Midstream Partners 352.8% in the second quarter.

13 September 2017
American International Group, Inc. (AIG) Shares Sold by Lipe & Dalton
Finally, Neuberger Berman Group LLC raised its stake in shares of American International Group by 1,334.1% during the 2nd quarter. The stock of American International Group Inc (NYSE:AIG) has "Sell" rating given on Monday, September 11 by Buckingham Research.